The Medical Device Business Journal — Medical Device News & Articles | MassDevice
The U.S. Supreme Court heard oral arguments this week in a case that could have wide-reaching implications for health care: Whether medical patents should be allowed.
At issue is the specter of doctors being sued for patent infringement based on treatment decisions derived from the scientific research underpinning the patent.
In a sudden switch, Conceptus (NSDQ:CPTS) named Keith Grossman president & CEO upon the resignation of Mark Sieczkarek, whose departure was announced on the heels of lowered sales guidance for 2012.
Sieczkarek’s resignation, after 7 years at the helm, was announced simultaneously with Grossman’s appointment. Grossman will join the company’s board of directors, from which Sieczkarek also resigned.
The U.S. Internal Revenue Service hit Boston Scientific (NYSE:BSX) with another huge tax bill over its 2006 acquisition of pacemaker firm Guidant Corp.
The latest tab, for $581 million plus interest and penalties, comes out of an IRS audit of Guidant’s books for 2004 through 2006, according to a regulatory filing.
Medtronic (NYSE:MDT) revealed that California attorney general Kamala Harris wants it to cough up documents on its controversial Infuse bone growth protein.
Its the latest in a line of subpoenas dating back to October 2008, when Massachusetts AG Martha Coakley requested documents related to Infuse.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
C.R. Bard Inc. (NYSE:BCR) plans to cut 50 jobs from its Queensbury, N.Y.-based manufacturing plant.
The 50 positions could be relocated outside the U.S., according to the Glen Falls, N.Y.-based Post Star. That would leave the Queensbury plant with roughly 770 employees.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Synthes CEO Michel Orsinger
Synthes CEO Michel Orsinger will land a $52 million payout to give up the corner office as part of the Swiss orthopedic device maker’s $21.3 billion buyout by med-tech titan Johnson & Johnson (NYSE:JNJ).
The deal, slated to close in early 2012, includes a $51.9 million payout to Orsinger for leaving Synthes and a multimillion-dollar stock package for his new position with Johnson & Johnson.
A nasty patent spat between Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. and Spectralytics, which a jury decided in the latter’s favor to the tune of $22.4 million, went another round this week after a judge added $500,000 to the damages award.
A nasty patent spat between Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. and Spectralytics, which a jury decided in the latter’s favor to the tune of $22.4 million, went another round this week after a judge added $500,000 to the damages award.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
